Human CD37 Protein

Cat. No. CD3-HM237



Description	
Source	Recombinant Human CD37 Protein is expressed from HEK293 with hFc tag at the N-Terminus.
	It contains Ala113-Asn240.
Accession	P11049-1
Molecular Weight	The protein has a predicted MW of 41.9 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

1 officialist and olorage	
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients.


Assay Data

Bis-Tris PAGE



Human CD37 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human CD37 is greater than 95% as determined by SEC-HPLC.